Mitchel L. Zoler, PhD
![1]()
News
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
June 16, 2020
In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.
![1]()
News
Entheseal lesions, bone density linked with incident PsA in psoriasis patients
June 11, 2020
Metacarpal entheseal lesions and low entheseal bone density in patients with psoriasis each linked with increased incident psoriatic arthritis.
![1]()
News
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
May 26, 2020
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
![1]()
News
Many hydroxychloroquine COVID-19 prophylaxis trials lack ECG screening
May 12, 2020
Posted designs for trial assessing hydroxychloroquine as COVID-19 prophylaxis lack ECG-based safety screening and discontinuation triggers.
![1]()
News
Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
May 4, 2020
Two single-center reports further documented the incidence of QTc-interval prolongations in COVID-19 patients treated with hydroxychloroquine.
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
April 29, 2020
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
![1]()
News
FDA reiterates hydroxychloroquine limitations for COVID-19
April 24, 2020
An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial.
![1]()
News
AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit
April 24, 2020
Adding aspirin to an anticoagulant and P2Y12 inhibitor showed no net benefit, even acutely, suggesting need to target aspirin to highly selected patients.
![1]()
News
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
April 22, 2020
A study drawing from 1,128 hypertensive, Chinese patients with COVID-19 suggested that those on an ACEI or ARB had better 28-day survival.
![1]()
News
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
April 21, 2020
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and reduced rates of VTE and aortic stenosis.
